Biography

Prof. Adam Reich

Department of Dermatology

University of Rzeszow, Poland
M.D., Ph.D.


Email: adi_medicalis@go2.pl


Qualifications

2006 Ph.D., University of Medicine, Wroclaw, Poland

2002 B.Sc., Humboldt-University, Berlin, Germany


Publications (Selected)

  1. Ficheux, A. S., Brenaut, E., Schut, C., Dalgard, F. J., Bewley, A., van Middendorp, H., ... & Misery, L. (2025). Predictors of perceived stress, perceived stigmatization and body dysmorphia in patients with chronic prurigo/prurigo nodularis: results from an observational cross-sectional multicentre European Study in 17 countries. Journal of the American Academy of Dermatology.
  2. Barker, J. N., Casanova, E., Choon, S. E., Foley, P., Fujita, H., Gonzalez, C., ... & Strober, B. (2025). Global Delphi consensus on treatment goals for generalised pustular psoriasis. British Journal of Dermatology, ljae491.
  3. Kołcz, K., Reich, A., & Żychowska, M. (2025). Application of Ultraviolet-Induced Fluorescence Trichoscopy (UVFT) in Hair and Scalp Diseases. Dermatology and Therapy, 1-21.
  4. Szczech, J., Walecka, I., Wolańska-Buzalska, D., & Reich, A. (2024). Assessment of the efficacy, tolerance, and regenerative properties of Cicaplast Baume B5+ Balm—results of an observational study. In Forum Dermatologicum (Vol. 10, No. 4, pp. 105-111).
  5. Kędra, K., & Reich, A. (2024). Clinical Utility of Various Formulations of Calcipotriene and Betamethasone Dipropionate for the Treatment of Plaque Psoriasis in Patients Aged 12 Years or Older. Drug Design, Development and Therapy, 5827-5839.
  6. Jachiet, M., Thaçi, D., Laquer, V. T., Lynde, C., Reich, A., Soong, W., ... & Gooderham, M. (2024). Efficacité et tolérance de l’inhibition de l’IL-22RA1 chez les patients atteints de dermatite atopique modérée à sévère: résultats d’un essai de phase 2a en monothérapie. Annales de Dermatologie et de Vénéréologie-FMC, 4(8), A371-A372.
  7. Gold, L. S., Bagel, J., Tyring, S., Hong, C. H., Pavlovsky, L., Pinter, A., ... & Papp, K. A. (2024). Efficacité du risankizumab versus aprémilast chez les patients atteints de psoriasis du cuir chevelu ou unguéal d’après l’étude de phase IV IMMpulse. Annales de Dermatologie et de Vénéréologie-FMC, 4(8), A359-A360.
  8. Kwatra, S. G., Legat, F. J., Reich, A., Simon, D., Naldi, L., Gil, Y., ... & Paul, C. (2024). Efficacité et sécurité à long terme du némolizumab jusqu’à 52 semaines dans l’étude d’extension ouverte OLYMPIA chez des patients atteints de prurigo nodulaire: analyse intermédiaire. Annales de Dermatologie et de Vénéréologie-FMC, 4(8), A342-A343.
  9. Ständer, S., Yosipovitch, G., Legat, F. J., Reich, A., Paul, C., Simon, D., ... & OLYMPIA 1 Investigators. (2024). Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial. JAMA dermatology.
  10. Kołt-Kamińska, M., Marek-Józefowicz, L., Krajewski, P., Nowowiejska, J., Siekierko, A., Duchnik, E., ... & Reich, A. (2024). Characteristics of Patients with Generalized Pustular Psoriasis: A Report of the Polish Generalized Pustular Psoriasis Group. Dermatology and Therapy, 1-15.
  11. Rossel, S. V. J., Reich, A., Baniel, A., Wertheim-Tysarowska, K., Frommherz, L. H., Nolberczak, D., ... & Gostyński, A. H. (2024). Exploring shared clinical features and successful therapeutic interventions in CARD14-associated papulosquamous eruption. Journal of the European Academy of Dermatology and Venereology: JEADV.
  12. Anderska, A., Kaczmarska-Such, A., Mazur, E., & Reich, A. (2024). Porokeratoses—A Rare Group of Dermatoses. Medicina, 60(11), 1876.
  13. Marron, S. E., Gracia‐Cazaña, T., Sampogna, F., Schut, C., Kupfer, J., Dalgard, F. J., ... & ESDAP Study Collaborators. (2024). Stigmatization and perceived health status in patients with hidradenitis suppurativa: an observational multicenter study in Europe. International Journal of Dermatology.
  14. Weidinger, S., Blauvelt, A., Papp, K. A., Reich, A., Lee, C. H., Worm, M., ... & Bernigaud, C. (2024). Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis. Journal of Allergy and Clinical Immunology.
  15. Krawczyk-Wołoszyn, K., Roczkowski, D., Reich, A., & Żychowska, M. (2024). Applying the Atomic Force Microscopy Technique in Medical Sciences—A Narrative Review. Biomedicines, 12(9), 2012.
  16. Otlewska-Szpotowicz, A., Matusiak, Ł., Salomon, J., Reich, A., & Szepietowski, J. (2024). SCALPDEX Questionnaire: creation and validation of the Polish language version. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 41(6), 590-593.
  17. Gooderham, M., Reich, A., Laquer, V., Lynde, C., Soong, W., Worm, M., ... & Thaci, D. (2024). 53111 Individual patient responses to IL-22RA1 inhibition in a Phase 2a monotherapy trial for moderate-to-severe atopic dermatitis. Journal of the American Academy of Dermatology, 91(3), AB239.
  18. Gold, L. S., Tyring, S. K., Hong, H. C. H., Pavlovsky, L., Pinter, A., Reich, A., ... & Papp, K. A. (2024). 50251 Efficacy of Risankizumab Versus Apremilast Among Patients with Scalp or Nail Psoriasis from the Phase 4 IMMpulse Study. Journal of the American Academy of Dermatology, 91(3), AB38.
  19. Krawczyk‐Wołoszyn, K., Żychowska, M., & Reich, A. (2024). Evaluation of hair surface structure and morphology of patients with lichen planopilaris (LPP) by atomic force microscopy (AFM). Skin Research and Technology, 30(9), e70030.
  20. Pinter, A., Gold, L. F. S., Bagel, J., Tyring, S. K., Vender, R., Reich, A., ... & Papp, K. A. (2024). 50250 Comparing the Effect of Risankizumab versus Apremilast on Psoriasis Symptoms, Treatment Satisfaction, and Health-Related Quality of Life from the Phase 4 IMMpulse Study. Journal of the American Academy of Dermatology, 91(3), AB165.
  21. Kołcz, K., Krawczyk-Wołoszyn, K., Reich, A., & Żychowska, M. (2024). Pruritus in Lichen Planopilaris and Frontal Fibrosing Alopecia—Clinical Characteristics and Dermoscopic Correlations. Journal of Clinical Medicine, 13(16), 4898.
  22. Narbutt, J., Jakubczak, Z., Wasiewicz-Ciach, P., Wojtania, J., Krupa, K., Sobolewska-Sztychny, D., ... & Lesiak, A. (2024). Effectiveness and Safety of Etanercept in Paediatric Patients with Plaque-Type Psoriasis: Real-World Evidence. Journal of Clinical Medicine, 13(16), 4858.
  23. Janke, T. M., Kozon, V., Valiukeviciene, S., Rackauskaite, L., Reich, A., Stępień, K., ... & Braren‐von Stülpnagel, C. C. (2024). Assessing health‐related quality of life using the W ound‐QoL‐17 and the W ound‐QoL‐14—R esults of the cross‐sectional E uropean HAQOL study using item response theory. International Wound Journal, 21(8), e70009.
  24. Sampogna, F., Samela, T., Abeni, D., Schut, C., Kupfer, J., Bewley, A. P., ... & European Society for Dermatology and Psychiatry (ESDaP) Study collaborators. (2024). A cross‐sectional study on gender differences in body dysmorphic concerns in patients with skin conditions in relation to sociodemographic, clinical and psychological variables. Journal of the European Academy of Dermatology and Venereology.
  25. Silverberg, J. I., Wollenberg, A., Reich, A., Thaçi, D., Legat, F. J., Papp, K. A., ... & Piketty, C. (2024). Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. The Lancet, 404(10451), 445-460.


Profile Details

https://orcid.org/0000-0002-5573-1754

https://scholar.google.com/citations?hl=zh-CN&user=--qpQVQAAAAJ

https://www.researchgate.net/profile/Adam-Reich

Free SCIRP Newsletters
Copyright © 2006-2025 Scientific Research Publishing Inc. All Rights Reserved.
Top